Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 12/20 | 1.00 |
| ▸ | MAPT | P10636 | 12/20 | 0.84 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.84 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.84 |
| ▸ | APP | P05067 | 5/20 | 0.81 |
| ▸ | CASP1 | P29466 | 2/20 | 0.81 |
| ▸ | MEN1 | O00255 | 1/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.81 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.81 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.81 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.81 |
| ▸ | APAF1 | O14727 | 1/20 | 0.80 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.80 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.80 |
| ▸ | CASP6 | P55212 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14660061 | 0.92 | MAPT (0.88) | ADORA1MAPTKDM4EALDH1A1ALOX12 | |
| SCHEMBL16379167 | 0.92 | MAPT (1.00) | ADORA1MAPTKDM4EALDH1A1ALOX12 | |
| SCHEMBL14659972 | 0.91 | ADORA1 (1.00) | ADORA1MAPTKDM4EALDH1A1ALOX12 | |
| SCHEMBL1491918 | 0.90 | MAPT (1.00) | ADORA1MAPTKDM4EALDH1A1ALOX12 | |
| SCHEMBL1491884 | 0.90 | MAPT (1.00) | ADORA1MAPTKDM4EALDH1A1ALOX12 | |
| SCHEMBL1491896 | 0.90 | MAPT (0.84) | ADORA1MAPTKDM4EALDH1A1ALOX12 | |
| SCHEMBL16379138 | 0.90 | MAPT (1.00) | ADORA1MAPTKDM4EALDH1A1ALOX12 | |
| SCHEMBL7885074 | 0.89 | MAPT (1.00) | ADORA1MAPTKDM4EALDH1A1ALOX12 | |
| SCHEMBL7877338 | 0.89 | MAPT (0.88) | ADORA1MAPTKDM4EALDH1A1ALOX12 | |
| SCHEMBL12023613 | 0.89 | MAPT (1.00) | ADORA1MAPTKDM4EALDH1A1ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6169087-B1 | Modulators of protein tyrosine phosphatases (PTPases) | NOVO NORDISK A/S (DK) | 2001-01-02 | — | — | US | claimed |
| EP-1017697-A1 | MODULES OF PROTEIN TYROSINE PHOSPHATASES (PTPases) | NOVO NORDISK A/S (DK) | 2000-07-12 | — | — | EP | claimed |
| WO-1999015529-A1 | MODULES OF PROTEIN TYROSINE PHOSPHATASES (PTPases) | NOVO NORDISK A/S (DK) | 1999-04-01 | — | — | WO | claimed |
| US-20150004100-A1 | HETEROCYCLIC COMPOUNDS AS IMAGING PROBES OF TAU PATHOLOGY | GE HEALTHCARE LIMITED (GB) | 2015-01-01 | — | — | US | disclosed |
| US-20150004100-A1 | HETEROCYCLIC COMPOUNDS AS IMAGING PROBES OF TAU PATHOLOGY | GE HEALTHCARE LIMITED (GB) | 2015-01-01 | — | — | US | disclosed |
| WO-2013090497-A1 | HETEROCYCLIC COMPOUNDS AS IMAGING PROBES OF TAU PATHOLOGY | GE HEALTHCARE LIMITED (GB) | 2013-06-20 | — | — | WO | disclosed |
| US-20130029983-A1 | AMINOTHIENOPYRIDAZINE INHIBITORS OF TAU ASSEMBLY | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2013-01-31 | — | — | US | disclosed |
| WO-2011037985-A1 | AMINOTHIENOPYRIDAZINE INHIBITORS OF TAU ASSEMBLY | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2011-03-31 | — | — | WO | disclosed |
| US-6169087-B1 | Modulators of protein tyrosine phosphatases (PTPases) | NOVO NORDISK A/S (DK) | 2001-01-02 | — | — | US | disclosed |
| EP-1017697-A1 | MODULES OF PROTEIN TYROSINE PHOSPHATASES (PTPases) | NOVO NORDISK A/S (DK) | 2000-07-12 | — | — | EP | disclosed |
| WO-1999015529-A1 | MODULES OF PROTEIN TYROSINE PHOSPHATASES (PTPases) | NOVO NORDISK A/S (DK) | 1999-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150004100-A1 | HETEROCYCLIC COMPOUNDS AS IMAGING PROBES OF TAU PATHOLOGY | MAPT, NAT1, APP | ADORA1 438/4885MAPT 1/4885KDM4E 4419/4885 |
| US-20130029983-A1 | AMINOTHIENOPYRIDAZINE INHIBITORS OF TAU ASSEMBLY | MAPT, PSEN1, PSEN2 | ADORA1 2590/4885MAPT 1/4885KDM4E 2737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.